Inventor · disambiguated record
Tjeerd Barf
Also filed as: BARF TJEERD · BARF TJEERD A · BARF TJEERD ANDRIES
30 granted patents·28 pending applications·177 citations·filing 1998–2023
96Inventor score
Top patents by PatentIndex Score
58 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0593US9796721B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2016·Granted Oct 24, 2017·12 cites·17 claims
- 0691US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0790US9790226B24-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Oct 17, 2017·8 cites·6 claims
- 0890US9758524B24-imidazopyridazin-1-yl-benzamides as Btk inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Sep 12, 2017·9 cites·14 claims
- 0990US9290504B24-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitorsBARF TJEERD A·Filed 2012·Granted Mar 22, 2016·37 cites·47 claims
- 1088US10239883B24-imidazopyridazin-1-yl-benzamides as BTK inhibitorsMERCK SHARP & DOHME·Filed 2017·Granted Mar 26, 2019·6 cites·14 claims
- 1186US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 1286US9718828B2BTK InhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Aug 1, 2017·7 cites·15 claims
- 1384US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 1484US6410585B1Inhibitors of protein tyrosine phosphataseFiled 1999·Granted Jun 25, 2002·36 cites·10 claims
- 1584US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1682US2024199622A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1780US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1880US2023331729A14-imidazopyridazin-1-yl-benzamides as btk inhibitorsMERCK SHARP & DOHME·Filed 2022·Application pending·0 cites
- 1978US11820777B2Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2022·Granted Nov 21, 2023·0 cites·27 claims
- 2078US10167291B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2017·Granted Jan 1, 2019·1 cites·28 claims
- 2177US11110088B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2020·Granted Sep 7, 2021·1 cites·2 claims
- 2273US7030135B2Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2001·Granted Apr 18, 2006·4 cites·8 claims
- 2373US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2472US2021230166A14-imidazopyridazin-1-yl-benzamides as btk inhibitorsMERCK SHARP & DOHME·Filed 2021·Application pending·0 cites
- 2571US11059829B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleateACERTA PHARMA BV·Filed 2020·Granted Jul 13, 2021·0 cites·42 claims
- 2671US10640509B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphomaACERTA PHARMA BV·Filed 2018·Granted May 5, 2020·0 cites·20 claims
- 2771US2022177476A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2869US10934296B24-imidazopyridazin-1-yl-benzamides as Btk inhibitorsMERCK SHARP & DOHME·Filed 2019·Granted Mar 2, 2021·0 cites·14 claims
- 2968US10736893B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2016·Granted Aug 11, 2020·1 cites·2 claims
- 3068US2010113435A1Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1BIOVITRUM AB·Filed 2009·Application pending·0 cites
- 3165US9102676B2MK2 inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted Aug 11, 2015·1 cites·8 claims
- 3264US7125900B2Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2001·Granted Oct 24, 2006·1 cites·2 claims
- 3364US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3463US7618961B2Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2001·Granted Nov 17, 2009·1 cites·3 claims
- 3562US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3661US2006287374A1Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2006·Application pending·0 cites
- 3760US8772286B2MK2 inhibitorsBARF TJEERD ANDRIES·Filed 2010·Granted Jul 8, 2014·1 cites·16 claims
- 3859US7094792B2Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2002·Granted Aug 22, 2006·1 cites·4 claims
- 3959US2006160797A1Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2005·Application pending·0 cites
- 4059US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 4158US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 4257US2020069668A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 4356US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4456US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 4555US7671051B2Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1BIOVITRUM AB·Filed 2005·Granted Mar 2, 2010·0 cites·7 claims
- 4655US2017035881A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4754US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4853US2025388602A1Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral InfectionsGENASE THERAPEUTICS B V·Filed 2023·Application pending·0 cites
- 4952US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 5051US2017224819A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →